NASDAQ:ORMP - Oramed Pharmaceuticals Stock Price, Forecast & News

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) issued its earnings results on Thursday, January, 9th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.11. The biotechnology company earned $0.67 million during the quarter. Oramed Pharmaceuticals had a negative return on equity of 38.51% and a negative net margin of 297.30%. View Oramed Pharmaceuticals' Earnings History.

Oramed Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, April 8th 2020. View Earnings Estimates for Oramed Pharmaceuticals.

2 Wall Street analysts have issued 1 year target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $7.00 to $20.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $13.50 in the next twelve months. This suggests a possible upside of 150.9% from the stock's current price. View Analyst Price Targets for Oramed Pharmaceuticals.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oramed Pharmaceuticals.

Media stories about ORMP stock have trended negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oramed Pharmaceuticals earned a daily sentiment score of -2.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Oramed Pharmaceuticals.

Oramed Pharmaceuticals saw a decline in short interest during the month of December. As of December 31st, there was short interest totalling 448,700 shares, a decline of 23.5% from the December 15th total of 586,300 shares. Based on an average daily trading volume, of 210,900 shares, the days-to-cover ratio is currently 2.1 days. Approximately 3.4% of the shares of the stock are short sold. View Oramed Pharmaceuticals' Current Options Chain.

Some companies that are related to Oramed Pharmaceuticals include Puma Biotechnology (PBYI), Evolus (EOLS), Recro Pharma (REPH), Avid Bioservices (CDMO), Spectrum Pharmaceuticals (SPPI), Syros Pharmaceuticals (SYRS), OptiNose (OPTN), Cue Biopharma (CUE), Stemline Therapeutics (STML), Satsuma Pharmaceuticals (STSA), 89bio (ETNB), CytomX Therapeutics (CTMX), INDIVIOR PLC/S (INVVY), Galera Therapeutics (GRTX) and MannKind (MNKD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Inovio Pharmaceuticals (INO), Zynerba Pharmaceuticals (ZYNE), Pluristem Therapeutics (PSTI), Gilead Sciences (GILD), NovaBay Pharmaceuticals (NBY), Caladrius Biosciences (CLBS) and Novavax (NVAX).

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ORMP stock can currently be purchased for approximately $5.38.

Oramed Pharmaceuticals has a market capitalization of $95.42 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis. View Additional Information About Oramed Pharmaceuticals.

The official website for Oramed Pharmaceuticals is http://www.oramed.com/.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]